• First Bitcoin Capital is advancing its status as a blockchain tech developer by acquiring the nation’s first bitcoin ATM patent, which it believes controls all bitcoin ATMs and kiosks in the United States
• First Bitcoin is preparing to enforce its patent rights, which it predicts should be worth more than $50 million in profits during the coming five years
• More than 3,000 bitcoin ATMs are currently operating in the United States, and an average of 3.7 bitcoin ATMs are being added each day
• First Bitcoin is also launching an ATM check-cashing service for unbanked payday customers, and it expects to add money order services and bitcoin buying/selling options through a nationwide network of SAMCO kiosks

First Bitcoin Capital Corp. (OTC: BITCF), a blockchain-powered technology developer that has created more than 100 unique cryptocurrencies during its history, is preparing to make a revolutionary leap in its revenue generation following its acquisition of the ‘bitcoin ATM patent’ (http://ibn.fm/COpsb), which it intends to use in governing the more than 3,000 bitcoin ATMs – and growing – operated in the United States.

Bitcoin ATMs are novel machines built on the model of a standard banking ATM, but they allow their users to instantly buy or sell bitcoin and other cryptocurrencies using cash or tokens, without any expectation of a bank account’s involvement in the transaction – although debit and credit cards are accepted.

The patent covers the mechanism that manages the purchase and sale of cryptocurrencies at the kiosks. Industry watcher Coin ATM Radar states that a daily average of 3.7 bitcoin ATM installations were occurring in the United States as of July (http://ibn.fm/ZUJco), and First Bitcoin stated in its news release announcing the acquisition that a business plan prepared by a third party predicts that the patent will bring in more than $50 million in profits over the coming five years.

The company is establishing its strategies for implementing an IP management plan, and it predicts that the patent could have a significant impact on the cryptocurrency industry itself.

“All bitcoin ATMs and kiosks manufactured and sold in the U.S., and all bitcoin ATMs and kiosks operated in the U.S. are believed to be subject to this patent and the company intends to enforce its right upon acquisition of same. The company has already begun negotiations with a major law firm that has a very successful track record in enforcing patent rights when working on a contingency basis,” the news release states (http://ibn.fm/FRYce).

Patenting bitcoin ATMs has been the subject of corporate competition in recent months. DNA Dynamics announced (http://ibn.fm/H3H2D) that it hoped to control “a crucial patent that requires any bitcoin ATM operator to give a royalty on every bitcoin ATM transaction throughout the U.S.,” for example, and Bank of America filed its own statement of interest (http://ibn.fm/4rehC) in technology that uses blockchain to “accelerate transaction speed and/or facilitate other types of transactions in addition to ATM transactions like cash withdrawals and deposits, such as gift registry transactions.”

“Being the first ever publicly traded company in the bitcoin and blockchain industry, we now have acquired one of the most important intellectual properties in this space, as we believe that this patent will provide us a unique and leveraged position, in addition to our other projects as we continue moving forward into the digital asset and cryptocurrency businesses,” First Bitcoin CEO Greg Rubin stated in a news release. “This patent complements our innovation in the field.”

First Bitcoin is developing its ATM presence by launching a pilot test program through which it has ordered Simple Automated Money, Inc. (SAMCO)’s S.A.M. kiosks to integrate bitcoin ATM into self-service check cashing kiosks nationwide, beginning with three kiosks in Northern California. The ATMs will grant unbanked consumers a fast and confidential check-cashing experience through SAMCO’s web-enabled units (http://ibn.fm/HBZSU).

First Bitcoin stated that it is expanding its California dispensary ATM locations to include C-stores and supermarkets. The company announced that it will also begin to add bitcoin buy/sell capabilities through the nationwide network of 85 SAMCO kiosks currently in operation, as well as money order processing and check cashing through touchscreen, biometric-secured access.

For more information, visit the company’s website at www.FirstBitcoin.io

• INmune Bio is currently attending the Cambridge Healthcare Institute’s 7th Annual Immuno-Oncology Summit in Boston
• Co-founder and CEO Dr. RJ Tesi is presenting positive preliminary data on INB03, which is being developed as part of a combination immunotherapy to potentially reverse resistance to treatment
• The annual immuno-oncology summit brings together leaders from across the immunotherapy industry and provides unique opportunities to connect scientists with the latest discoveries in the field

An international mix of thought leaders and decision makers from the international immunotherapy and immuno-oncology community are gathering in Boston this week, with INmune Bio co-founder and CEO Dr. RJ Tesi slated to deliver several presentations. A news release outlining Tesi’s agenda at the five-day Cambridge Healthcare Institute’s 7th Annual Immuno-Oncology Summit highlights INmune Bio Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness patients’ innate immune systems to fight disease (http://ibn.fm/4pBdZ).

“We are committed to helping treatment-resistant patients by advancing the clinical development of combination therapies and other effective cancer treatments,” Tesi stated in a news release. “I am delighted to have the chance to present with some of the most prominent leaders in the immuno-oncology community.”

A fast-growing cancer patient population that is resistant to checkpoint inhibitors (“CPI”) was the focus of Tesi’s presentation on Monday, August 5, under the title ‘Targeting Soluble TNF to Improve Efficacy of Combination Immunotherapy’. During his presentation, Tesi reported positive preliminary data from the company’s INB03 Phase I clinical trial in cancer patients (http://ibn.fm/m1Iy3).

“The goal of the Phase I study is to determine, in order of priority, the safety of INB03 in cancer patients, the dose of INB03 to take into the Phase II trials in cancer, and evidence of a biologic effect of INB03,” continued Tesi, who is also INmune Bio’s chief medical officer. “All of these goals have been met. Using data from this trial, we have begun planning a Phase II trial using INB03 as part of combination immunotherapy in patients with cancer.”

The Phase I trial is an open-label, dose-escalation trial in patients with advanced solid tumors. Patients received INB03, a novel, second-generation soluble TNF (tumor necrosis factor) inhibitor that works by leveraging a dominant-negative technology. Positive preliminary data from the first two cohorts were released. That data will be followed by a final report later this year as the company advances the program into a Phase II study.

Tesi is also speaking on ‘Next-Generation Immunotherapies’ and ‘Targeting ‘Protector’ Cells of the Innate Immune System’ during the summit. The Cambridge Healthcare Institute’s annual immuno-oncology summit brings together leaders from across the immunotherapy industry and provides a unique opportunity to network with decision-makers, build lasting collaborations and gain actionable solutions.

INmune Bio also recently attended the 17th Annual Congress of International Drug Discovery Science & Technology in Japan, where Tesi gave a talk titled ‘Combination Immunotherapy to Overcome Resistance to Cancer Treatments’. His presentation centered on monotherapy with checkpoint inhibitors (“CPI”) as an effective treatment option. The combination of CPI and other therapies may improve outcomes in patients who are unresponsive to monotherapy, an article explains (http://ibn.fm/EFAdX).

INmune Bio’s product pipeline targets three segments of concern: Alzheimer’s disease/dementia, which claims 5.5 million patients in the U.S.; cancer residual disease, which is expected to generate more than 1.7 million new cases yearly; and resistance to immunotherapy. INmune Bio is currently working on three product platforms: INKmune and INB03, which modify a patient’s innate immune response to cancer; and XPro1595, which targets inflammation linked to Alzheimer’s disease.

For more information, visit the company’s website at www.INmuneBio.com

NOTE TO INVESTORS: The latest news and updates relating to INMB are available in the company’s newsroom at http://ibn.fm/INMB

• Financial results for the second quarter of 2019 have Trxade Group’s managerial team optimistic about the future of the brand and its digital platforms
• The company already has over 10,500 members for its pharmacy trading platform
• Independent pharmacies face many challenges when it comes to securing cost-efficient drugs, and Trxade Group has the technology to address these issues and continue building new industry-relevant products in the future

Trxade Group Inc. (OTCQB: TRXD), an integrated pharmaceutical logistical service company, expects its new product lines to generate profitability in the coming months of 2019 and beyond, CEO and chairman Suren Ajjarapu said after the company announced its financial results for the second quarter of 2019.

“In response to customer demand, we are actively developing new product offerings with increased data analytics capability which will help independent pharmacies better manage their inventory and costs,” Ajjarapu stated in a company news release (http://ibn.fm/aprPi).

Trxade Group brings together web-based purchasing platforms for independent pharmacy and drug manufacturer transactions, a mail order pharmacy E-Hub and warehouse and drug delivery services for consumers across the U.S. For the quarter ended June 30, 2019, the company registered record revenue of $1,916,414, marking a massive increase from the $837,688 reported for the same period of 2018. In addition, gross profits for the three-month period went up to $1,163,276 from $837,688 in 2018. Operating income also went up. The company attributed this growth to its independent pharmacy acquisition. These results marked the eighth consecutive quarter during which the Trxade platform reported record quarterly operating costs.

By the end of June 2019, Trxade had registered 390 new independent pharmacies via the platform, marking an increase of 24 percent from the previous quarter and 137 percent on an annual basis. In addition, the company’s consumer app, www.Delivmeds.com, added 94 new independent pharmacies to expand the B2C delivery network of the platform.

Through the network increase achieved in the second quarter of 2019, membership for the TRXD trading software has gone up to 10,500 pharmacies. There are over 24,000 independent pharmacies in the U.S., and their combined pharmaceutical purchase capabilities exceed $93 billion per year.

Many independent pharmacies in the U.S. are limited in terms of time and resources for the purchase of medications. These pharmacies often struggle to maintain margins, which has made them turn to sourcing programs and other opportunities in the past to reduce the purchase cost of drugs. Rising fees and reduced reimbursements, however, have contributed to declining margins for independent pharmacies over the past decade.

Trxade Group offers independent pharmacies a real opportunity to reduce purchase costs while also benefiting from a fully integrated web service. The Trxade platform (Trxade Exchange) isn’t just there to facilitate the cost-efficient acquisition of drugs; it also creates a network of associated pharmacies and gives smaller industry representatives access to a wider supply chain network. This way, pharmacies can view different products and manufacturers, buying groups and wholesalers on a real-time basis.

The size of the industry and the exceptional financial results that Trxade Group registered in the second quarter of 2019 have the company’s managerial team optimistic about the future of both B2B and B2C pharmaceutical service provision.

For more information, visit the company’s website at www.TrxadeGroup.com

NOTE TO INVESTORS: The latest news and updates relating to TRXD are available in the company’s newsroom at http://ibn.fm/TRXD

• Lexaria’s patented DehydraTECH technology improves taste, achieves higher absorption rates and promotes fast onset of bioactive compounds, including nicotine and cannabinoids
• Nine corporate licensees have signed a total of 11 definitive contracts to use DehydraTECH technology in innovative beverages, edibles and oral products
• Lexaria expects to experience unprecedented revenue growth as many of its clients plan aggressive rollouts and growth for their product lines

Biotechnology company and drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is expanding its family of existing licensees and partners with an impressive lineup of new corporate licensees for use of Lexaria’s patented DehydraTECH absorption technology. A total of nine corporations have signed 11 definitive contracts to use Lexaria’s revolutionary DehydraTECH drug delivery platform within their existing and emerging brands, as the company detailed in a recent news release (http://ibn.fm/tkN6e).

“The first half of 2019 delivered a period of unprecedented achievements for Lexaria,” CEO Chris Bunka stated in a news release. “We signed more license agreements than ever before in our Company’s history, many of which were larger in scope than anything previous. We also launched our brand-new business division Lexaria Nicotine which is disrupting nicotine delivery methods that already attracted one of the world’s largest nicotine companies, which has licensed our technology.”

Lexaria recently announced that it has discovered improved performance characteristics in a new version of its DehydraTECH delivery platform. An innovative use of a naturally sourced formulation enhancement more than doubles DehydraTECH’s absorption performance, the company stated in a news release (http://ibn.fm/9sZRc), making the technology suitable for use in solid oral dosage forms like capsules, tablets and pills for the pharmaceutical, medical and supplement markets. New patent applications related to the recent innovations have been filed.

Lexaria credits its recent commercial success mainly to its ever-growing body of scientific results evidencing the superior capabilities and power of its patented technologies. Recent technological advancements are the result of one of the industry’s most focused and productive R&D programs and hold promise for even higher levels of performance. In one 2019 animal study, combining Lexaria’s DehydraTECH with nanotech technologies delivered increased quantities of CBD into brain tissue following oral ingestion than certain existing industry formulations (http://ibn.fm/vWbd5).

Among the companies taking notice of Lexaria’s DehydraTECH drug delivery platform by signing new license contracts are:

• Altria Ventures Inc., an indirect wholly owned subsidiary of Altria Group Inc., for oral nicotine products; this license is signed with Lexaria Nicotine LLC, a separate business division of Lexaria Bioscience Corp;
• Nuka Enterprises LLC, for a new CBD/hemp license for beverages across the U.S.;
• Two new worldwide beverages licenses to Hill Street Beverages (excluding Mexico);
• Two new joint manufacturing production licenses with Hill Street Beverages for new, jointly owned cannabis and CBD brands;
• Three new licenses with other companies for CBD beverages and edible CBD ingredients/products across the U.S.;
• One new license for cannabis beverages in California; and
• One new multistate cannabis expansion license with Nuka Enterprises LLC for its 1906 Brands for five states and two new product categories.

Lexaria expects to sign additional new definitive license agreements through the balance of 2019 and beyond as demand for its industry-leading technology continues to increase. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the U.S. and Australia for utilization of its DehydraTECH delivery technology.

For more information, visit the company’s website at www.LexariaBioscience.com

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP

• Grapefruit recently filed a registration statement with the SEC
• The company is one of the earliest registered cannabis distribution firms to attain an annually renewable license
• Following the registration statement, Grapefruit’s second funding tranche is expected to be released this week

California-based Grapefruit Boulevard Investments Inc. (OTCQB: IGNG), a fully licensed premier cannabis manufacturer and distributor in the California legal cannabis marketplace, has filed a registration statement with the SEC on Form S-1 to register shares of the company’s common stock underlying the $600,000 convertible note recently issued to an institutional investor, as well as other securities to be issued to the investor (http://ibn.fm/K86Ke). This filing is an important achievement for Grapefruit in its quest to become a premier cannabis company, boasting quality control and attention to detail from production to distribution.

Headquartered in Los Angeles, California, Grapefruit holds licenses to both manufacture and distribute cannabis products. It also has its own branded product lines. The company is well focused on sourcing only the best-of-the-best raw cannabis materials in its mission to create the highest-quality, most trusted and most consistent recreational and medical cannabis products for its customers.

Despite its booming scale, the cannabis industry is not without its challenges. In 2018, the legal cannabis industry experienced one of its slowest annual expansion rates since Colorado launched the adult-use era in 2014. In California, legal spending on cannabis fell from $3 billion in 2017 to $2.5 billion during the year in which the state implemented an adult-use regulatory regime. A key takeaway from the California market is that highly restrictive regulations and high tax rates may be hurting the legal market’s ability to compete with the illicit market (http://ibn.fm/Gupy0). However, Grapefruit is poised with an industry advantage as one of the few vertically integrated cannabis companies.

Grapefruit holds its State of California provisional licensing from the Bureau of Cannabis Control and the California Department of Public Health. The company is one of the earliest registered distribution companies with the state to have an annually renewable license, as opposed to the temporary licenses previously granted.

The regulatory changes have impacted the ability of new businesses to enter the marketplace and compete with Grapefruit. However, none of Grapefruit’s commercial cannabis businesses have been impacted by the regulatory changes to the marketplace. Grapefruit understands the state’s regulatory burdens and is fully compliant with all applicable laws and regulations.

Now that Grapefruit has filed a registration statement, it is well-positioned to experience significant growth. The investor is required to fund the second tranche of $1.4 million in accordance with the terms of the securities purchase agreement. Grapefruit anticipates that the second tranche will be funded this week.

“The filing of the registration statement is the timely achievement of yet another publicly stated goal of the company,” Grapefruit CEO Bradley J. Yourist stated in a news release. “Moreover, the infusion of an additional $1,400,000.00 of capital will allow IGNG/Grapefruit to, as expeditiously as possible, exploit significant revenue opportunities available to it and to move forward with its business plan as we move inexorably toward our goal of becoming the leading fully integrated, licensed and compliant cannabis product manufacturing and distribution company.”

Yourist concluded, “We are pleased that another important box has been checked on time.”

Grapefruit’s goal is to become a vertically integrated, seed-to-sale cannabis and CBD product company serving the California market. Moreover, the company plans to roll out its product lines in other states, including Nevada, Illinois, Oregon, Colorado and Washington. Grapefruit’s motto – ‘A High You Can Trust’ – embodies its philosophy and ethos, reminding consumers of the company’s commitment to manufacture, procure and distribute only the highest-quality, all-natural cannabis flower, concentrates and products.

Grapefruit Boulevard Investments is a wholly owned subsidiary of Imaging3.

For more information, visit the company’s website at www.GrapefruitBlvd.com

NOTE TO INVESTORS: The latest news and updates relating to IGNG are available in the company’s newsroom at http://ibn.fm/IGNG

• Lexaria Bioscience’s revolutionary DehydraTECH technology enables cannabis consumers to experience rapid-on, rapid-off effects in non-smoked formulations
• A just-announced joint manufacturing partnership between Lexaria and alcohol-free beverage maker Hill Street Beverage Company is paving the way for wider distribution of Lexaria’s platform
• Hill Street is the only company to have gained licenses to use DehydraTECH on a global basis, taking advantage of Lexaria’s multiple international granted and pending patents
• By 2024, cannabis-infused beverage sales are expected to rise by nearly 15 times from last year’s revenues of $89 million

The exploding interest in cannabis products and in new ways of enjoying them has proven fertile ground for drug technology innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) as it markets the company’s revolutionary DehydraTECH platform for increasing the absorption rates of varied edible substances, including nicotine and cannabidiol (CBD).

DehydraTECH is a drug delivery technology that gets ingested active pharmaceutical ingredient (API) molecules to the bloodstream faster than other methods. Under a new agreement announced July 24, the company will expand DehydraTECH’s reach by allowing Hill Street Beverage Company Inc. (TSX.V: BEER), a manufacturer of alcohol-free and cannabis-infused beer, wine, and adult format beverages, to produce commercial products in partnership with Lexaria under a new brand that is yet to be announced (http://ibn.fm/BTodZ).

The new brand will include processed tetrahydrocannabinol (THC) and/or cannabidiol (CBD) powder ingredients from cannabis for the Canadian market. The agreement will be in force for 10 years. Both companies expect the arrangement to create the potential of enhanced cashflow, and Lexaria, in particular, is anticipated to benefit from the emerging federally legal cannabis edibles industry in Canada, where edible cannabis products will be allowed under new laws beginning in October.

The new joint manufacturing partnership will create a mechanism for intermediate ingredients made from DehydraTECH-processed cannabis and hemp powders to be sold for the first time on a business-to-business (B2B) basis between Canada’s licensed producers and other businesses licensed by Health Canada to make cannabis-infused edibles. The powders are stable, with a two-to-three-year shelf life, and are odorless and tasteless, providing a full-spectrum cannabis experience for nearly any ingestible product format.

“When we first began our relationship with Lexaria it was based on a comprehensive competitive review of the market with a single uncompromising vision: to find a technology partner who could provide water soluble cannabis, with zero impact on the award-winning taste and aroma of our products,” Terry Donnelly, chairman and CEO of Hill Street, stated in a news release. “This partnership takes our relationship to a whole new level, which we believe will help to set a global standard for excellence that consumers are looking for in cannabis edibles and beverages.”

In addition to the rapid onset of ingested cannabis’ effect enabled by DehydraTECH, the technology creates a mechanism for stronger peak delivery of the effect through higher peak blood concentrations, as demonstrated in third-party lab tests. The technology also delivers the benefit of a “fast-off” effect, with the initial peak followed four hours later by lower cannabinoid content in the blood than some competitors’ nanotech-enabled formulations, leading to a shorter-duration experience that many consumers prefer as they resume other activities.

Hill Street is the only company to gain semi-exclusive licenses to use the DehydraTECH CBD beverage infusion technology in global markets around the world. DehydraTECH has received 11 patents in the United States and Australia and has about 60 additional patents pending in more than 40 countries worldwide.

Food and drink consultancy Zenith Global predicts that the U.S. market for cannabis- and hemp-infused drinks will balloon by nearly 15 times last year’s revenues of $89 million to over $1.4 billion by 2024 (http://ibn.fm/PgbKH).

For more information, visit the company’s website at www.LexariaBioscience.com

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP

• Prelaunch of the company’s cannabis delivery service, Viva Buds Inc., was recently announced, with signups now being accepted as the official August launch date nears
• MCOA’s revolutionary, nourishing cosmetic topical CBD formula, hempSMART Body Cream, is designed to set a new industry standard by helping to improve overall skin health
• The company’s expansion of wholly owned subsidiary hempSMART Ltd. into Europe continued with its recent entry into the Netherlands

Marijuana Company of America Inc. (OTCQB: MCOA), an innovative hemp and cannabis corporation, continues to expand its portfolio with new products and avenues of customer service. As pioneers in the cannabis industry, dating back to 2009 when MCOA CEO Don Steinberg founded the first marijuana company ever to trade on a U.S. stock market (Medical Marijuana Inc.), MCOA has stayed at the forefront of the cannabis and hemp industry.

The establishment of a joint venture with Natural Plant Extract of California (“NPE”), along with a 20 percent ownership stake in the company, led to the creation of Viva Buds Inc., a unique, Los Angeles, California-based cannabis delivery service. MCOA’s commitment to the joint venture is evident in a recent news release (http://ibn.fm/rLE91) announcing the acceptance of potential customers during a prelaunch of Viva Buds’ cannabis delivery service in the San Fernando Valley in the Los Angeles area.

Interested adult consumers can sign up now at www.VivaBuds.com, which will give customers several advantages before the official August 2019 launch date, including the ability to build their own personal cannabis business utilizing a “call your friend” approach (http://ibn.fm/mIiIY).

The joint venture calls for MCOA and NPE to share in the net profits on a 50-50 basis, with NPE managing all operations pertaining to distribution, manufacturing and delivery of cannabis products, while MCOA provides capital, consulting and marketing services. “It’s an innovative opportunity in one of the largest U.S. markets for recreational cannabis,” Steinberg said in a news release.

MCOA’s hempSMART brand is also launching a revolutionary, nourishing topical CBD-infused cosmetic product called hempSMART Body Cream (http://ibn.fm/VWB5S). Each bottle of hempSMART Body Cream is formulated with 300 mg of organically grown, full spectrum, non-psychoactive cannabidiol derived from industrial hemp.

“Combining premium CBD oil with a unique blend of synergistic Ayurvedic herbs and botanicals illustrates a major advancement in the wellness arena,” added Paula Vetter, a holistic nurse practitioner and certified herbalist who is also chair of the hempSMART medical advisory board. “The cream is completely free of toxins that are commonly found in many skin care products and absorbed through the skin and into the blood stream… Instead, hempSMART’s Body Cream is a topical wellness solution that sets a new standard in the industry by improving the overall health of skin with each use.”

The hempSMART product line distinguishes itself from competitors through its premier quality extracts derived from industrial hemp plants grown specifically to provide the highest concentration of CBD. In fact, hempSMART products received such positive feedback during a launch in the United Kingdom in March 2019 that MCOA was encouraged to expand its European footprint into the Netherlands through its wholly owned subsidiary, hempSMART Ltd., in June 2019 (http://ibn.fm/7p9YG).

“The Netherlands launch was a complete success, with people traveling from other parts of Europe to witness the excitement around our hempSMART CBD product line,” Ian Harvey, global sales director of hempSMART, noted. “The event featured our CEO, Don Steinberg, unveiling our wellness products via video link and educating people about the benefits of our prime quality botanical ingredients. Our products sold out at the end of the event, and we engaged new marketing associates for hempSMART as evangelists to the brand that will help spread our vision.”

For more information, visit the company’s website at www.MarijuanaCompanyofAmerica.com

NOTE TO INVESTORS: The latest news and updates relating to MCOA are available in the company’s newsroom at http://ibn.fm/MCOA

• Blue Hat reported 52 percent revenue growth and 76 percent net income growth for the nine months ended September 30, 2018
• The company maintains a vast portfolio of proprietary technologies, patents, artwork copyrights, trademarks and software copyrights
• Retail sales of toys and games in China surged from RMB111.8 billion in 2012 to RMB276.6 billion in 2017
• Global trends and government policies favor further growth

The toy industry is not a frivolous pastime. In fact, the toy business offers a wealth of opportunity. The United States is currently the largest segment of global toy sales. However, in terms of growth prospects, the toy market in Asia is on a tear, growing by a whopping 20 percent from 2012 to 2017. China’s market for toys and video games, now worth $45 billion, is expected to bypass America in just a few years (http://ibn.fm/pQrXP). With this expansion, modern consumers are looking for unique products that go far beyond the typical and deliver a wow factor.

Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT) delivers that wow factor, creating the toys and games that parents want and children enjoy. Blue Hat is a leading innovator, producer and operator of augmented reality (AR) interactive entertainment games and smart toys in China. Retail sales of toys and games in China surged from RMB111.8 billion in 2012 to RMB276.6 billion in 2017, and Blue Hat is at the vanguard of this growth.

Blue Hat reported eye-popping 76 percent net income growth in the nine months ended September 30, 2018, serving as obvious evidence that the company’s toys, games and educational products are being embraced by the public. Such explosive growth far outpaces the growth of the industry and may be indicative of what’s to come.

Blue Hat’s popular product lines include mobile games, interactive educational materials and toys with built-in mobile game features. The company’s sophisticated mobile-connected entertainment platform enables the connection of physical items to mobile devices through wireless technologies, creating a vibrant interactive user experience.

Utilizing state-of-the-art technology, Blue Hat employs augmented reality (AR), motion capture technology, image recognition technology, voice control, light sensing technology, infrared, levitation induction and proprietary techniques to create toys and games that children love. The company also combines AR technology with education by integrating its products into situational teaching, roleplaying and man-machine interaction use cases.

With more products in development, Blue Hat currently has 161 authorized patents, 56 registered trademarks, 645 copyrights and 25 software copyrights. The company has developed sales channels and long-term relationships with preferred distributors. Its AR interactive entertainment products are sold in well-known international retail chains such as Toys ‘R’ Us, as well as other retail outlets. Blue Hat also has integrated online and offline sales channels with e-commerce giants like Alibaba, and it owns a busy brick and mortar store in Xiamen, China.

For more information, visit the company’s website at www.BlueHatGroup.net

NOTE TO INVESTORS: The latest news and updates relating to BHAT are available in the company’s newsroom at http://ibn.fm/BHAT

• BMW is among the leaders in the automotive industry in its efforts to improve environmental sustainability through the use of natural, biodegradable products and electrical power systems that eliminate carbon emissions
• The company’s BMW i sub-brand utilizes natural hemp fibers in strong biocomposites for vehicle bodies that provide environmentally friendly appeal while maintaining physical integrity
• BMW’s i3 was the among the top-three best-selling all-electric vehicles for three years in a row, demonstrating the market demand for BMW’s vision of earth-friendly production

Pioneers crossing the North American Great Plains during the 19th Century used hemp canvas to outfit their covered wagons and protect them from the ravages of nature. In the 21st Century, automobile drivers crossing vast tracts of land at much greater speeds in vehicles manufactured by BMW Group (OTC: BMWYY) may be traveling in models that upgrade hemp’s utility in strong biocomposites to protect nature from the ravages of mankind.

BMW made waves with the introduction of its electric vehicle BMW i sub-brand in 2011 (http://ibn.fm/2KpMS) to showcase its vision for futuristic body designs using renewable and recycled materials, exemplified by the launch of its first “zero emissions” mass-produced vehicle, the i3, in 2013 and its companion i8 model (http://ibn.fm/jmOmt). The i3 was the first large-volume vehicle on the market to feature carbon-fiber reinforced plastic (“CFRP”), a very lightweight material incorporating hemp biocomposites to help make it more biodegradable while exhibiting two to three times the strength of steel (http://ibn.fm/uBTbF).

For three years in a row, through 2016, the i3 was ranked third by worldwide sales among all-electric cars (http://ibn.fm/B5dEf), demonstrating the market demand for BMW’s approach to automobiles with a smaller carbon footprint. The company boasts that 95 percent of the i3’s materials are recyclable.

Worldwide, the number of electric vehicles on the road grew by 54 percent in 2017 as concerns about global climate change, believed to be a result of human-caused pollution, led a multinational governmental policy response in the form of the Paris Agreement, which calls for the evolution of the petroleum-fueled auto industry (http://ibn.fm/Bi5XT).

California announced that it plans to have 5 million electric vehicles on its roads by 2025, and at least eight other U.S. states followed its lead in establishing an annual sales target of 15.4 percent electric vehicles as part of the total auto trade (http://ibn.fm/5iDiW). China is leading global sustainability efforts, with plans for 2 million EV sales by 2020. The nation reported that its sales of EVs already topped 1.1 million during 2018, marking more than 55 percent of all electric vehicles sold worldwide at a time when U.S. electric vehicle sales were at just 358,000 (http://ibn.fm/gY6lW).

Automakers’ use of natural fibers such as hemp are one example of efforts to improve ecological sustainability by increasing fuel economy, lightening vehicle weight, reducing use of nonbiodegradable plastics, and pairing vehicles with EV energy trains, thereby eliminating the carbon emissions that petroleum adds to the atmosphere.

For more information, visit the company’s website at www.BMWGroup.com

• INmune Bio attended the 17th Annual Congress of International Drug Discovery Science & Technology in Japan
• Co-founder and CEO R.J. Tesi and Director of Neuroscience C.J. Barnum both participated in talks about the role of immunotherapy in the treatment of specific medical conditions
• The congress was a paramount event in the field of immunotherapy, allowing researchers to network, exchange ideas and discuss recent developments

INmune Bio Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness patients’ innate immune systems to fight disease, presented its innovative cancer immunotherapy, as well as its Alzheimer’s disease drug candidate, during a major immunotherapy industry congress.

The 17th Annual Congress of International Drug Discovery Science & Technology, held on July 26 in Japan, brought together several immunotherapy industry leaders and provided excellent networking opportunities while facilitating the exchange of ideas and recent developments in the industry, as the company noted in a press release (http://ibn.fm/fzlta).

At the congress, INmune Bio co-founder and CEO R.J. Tesi, M.D, gave a talk titled ‘Combination Immunotherapy to Overcome Resistance to Cancer Treatments’, which highlighted monotherapy with checkpoint inhibitors (CPI) as an effective treatment option. The combination of CPI and other therapies may improve outcomes in patients who are unresponsive to monotherapy, Tesi explained.

INmune Bio Director of Neuroscience C.J. Barnum also delivered a presentation on immunological disease and neurodegenerative disease, titled ‘Neurodegenerative Disease as an Immunological Disease: Role of Biomarkers’. The presentation focused on the link between neuroinflammation and Alzheimer’s disease, as well as the INmune phase I trial evaluating the treatment of patients with dementia through a precision medicine approach.

The company’s innovative drug candidate, XPro1595, targets neuroinflammation. It works by affecting microglial immune cells in the brain. Research suggests that these cells get activated in many patients with Alzheimer’s disease, contributing to neuroinflammation and promoting synaptic dysfunction.

A phase I clinical trial of XPro1595 involves 18 patients and is expected to continue throughout the summer of 2019. INmune Bio aims to measure both traditional and novel biomarkers in the patients to assess inflammation in those who have mild to moderate Alzheimer’s disease. The Alzheimer’s Association is providing financial support for the clinical trial in the form of a $1 million grant.

As the prominence of Alzheimer’s disease increases, seeking an adequate treatment option is becoming a more important task than ever before. Studies show that the prevalence of Alzheimer’s disease doubles every five years, and it already affects 40 percent of the population in the 90-94 age group (http://ibn.fm/2HX7N). The prevalence of Alzheimer’s disease is also anticipated to grow in the 65+ age group. In 2000, 6.8 percent of people in that age group were affected, but the figure will reach 16.2 percent by 2050.

INmune Bio is a publicly traded clinical-stage biotechnology company focusing on the development of therapies that target the immune system to fight or control disease. Currently, the company is working on three product platforms – two products that modify patients’ innate immune responses to cancer and one product, XPro1595, that targets neuroinflammation linked to Alzheimer’s disease. All of the INmune Bio product platforms utilize a precision medicine approach for the treatment of a variety of hematologic malignancies, solid tumors and chronic inflammation.

For more information, visit the company’s website at www.INmuneBio.com

NOTE TO INVESTORS: The latest news and updates relating to INMB are available in the company’s newsroom at http://ibn.fm/INMB